Long Ideas - Navidea Biopharmaceuticals (NASDAQ:NAVB) announced that on October 30th it resubmitted its new drug application (NDA) for Lymphoseek in response to the FDA’s Complete Response Letter … Continue Reading
Read NowLong Ideas - The biotechnology sector can be broken up, at its simplest, into two distinct groups: the Big 4, and every other company. The Big 4 are … Continue Reading
Read NowLong Ideas - Acorda Therapeutics (NASDAQ:ACOR) reported 3Q 2012 revenues and EPS of $77.4 million and $0.24, vs. the Consensus estimates of $75.1 million and $0.10, respectively. Sales … Continue Reading
Read NowLong Ideas - In a move that management says will save the company more than $100M over the next three years, AVEO Oncology (NASDAQ:AVEO) cut its work force … Continue Reading
Read NowLong Ideas - Despite a stash of cash and liquid investments, Lexicon Pharmaceuticals (NASDAQ:LXRX) caught investors off guard two weeks ago by initiating a capital raise. The company … Continue Reading
Read NowLong Ideas - Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) have been under pressure as investors await the supply of generic leucovorin to increase and compete with SPPI’s branded cancer … Continue Reading
Read NowLong Ideas - While investors have been focusing their attention on palifosfamide and the upcoming phase III data, Ziopharm (NASDAQ:ZIOP) released some initial phase I data of Ad-RTS IL-12 … Continue Reading
Read Now